Rufinamide
Back to Test Catalogue
Rufinamide, Serum/Plasma
Test ID: RUFIN
Test
Method
Chromatography/MS
Report Includes
Specimens
Avoid gel separator tubes; Serum; Plasma (EDTA)
Clinical Utility
Rufinamide is an antiepileptic indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children and adults. As multiple antiepileptics may be administered, it may be important to (1) optimize therapy, (2) monitor compliance, and (3) avoid toxicity.
Source: https://testdirectory.questdiagnostics.com/test/test-detail/16296/rufinamide?p=r&q=rufinamide&cc=MASTER; Accessed 10-Jul-2019.
Test Location
Quest Diagnostics, California USA
Test Version
30-Sep-2019
Specimen
Specimens
Avoid gel separator tubes; Serum; Plasma (EDTA)
Sample Volume
1 mL
Minimum Volume
0.5 mL
Specimen Comment
Avoid gel separator tubes.
Collection & Handling
Collection Instructions
Collect trough specimen within 1 hour prior to next dose.
Handling Information
Store and send cold.
Stability
| Ambient | 7 days |
|---|---|
| Refrigerated | 30 days |
| Frozen | 30 days |
Rejection Criteria
| Specimen | Gel-separator |
|---|
Test Version
30-Sep-2019
Performance / Interpretation
Method
Chromatography/MS
Turnaround Time
7 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| Rufinamide | µg/mL |
|
||
|
Maintenance therapy with 45 mg/kg (approximately 1600 mg) daily Rufinamide resulted in plasma concentrations ranging from 5.0 - 55.0 µg/mL
|
||||
Test Location
Quest Diagnostics, California USA
Test Version
30-Sep-2019
Interface / Setup
Test Version
30-Sep-2019